Tasneem Drie’s research while affiliated with Damascus University and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (13)


Treatment of recurrent uveitis and ankylosing spondylitis with Golimumab: a case report, Letter to Editor
  • Article
  • Full-text available

July 2024

·

10 Reads

Annals of Medicine and Surgery

Maysoun Kudsi

·

Tasneem Drie

·

Sumaya Dumirieh

Introduction and Importance Uveitis, as an extra-articular presentation, is found in 23% of patients with Ankylosing Spondylitis and is a challenging disease to treat. Case presentation we presented A 32-year-old male presented to the out-hospital, complaining of recurrent anterior uveitis 8 years earlier in his left eye, and suffered from inflammatory lumber pain for 2 years. so a diagnosis of Ankylosing Spondylitis(AS) after the failure of many therapeutic strategies, 50 mg /month subcutaneous Golimumab was started with clinical remission of AS and uveitis. Clinical discussion The American College of Rheumatology ¹⁰ recommends the use of etanercept and adalimumab in the treatment of recurrent uveitis in AS patients. Similarly, the European League Against Rheumatism ¹¹ recommended using Infliximab, Adalimumab, or Certolizumab to prevent the recurrence of uveitis recurrence. Till now, a case about treating refractory uveitis with Golimumab in AS patients was published1. Conclusion Golimumab was found to be effective in the treatment of uveitis associated with spondyloarthritis refractory at least one immunosuppressive drug.

Download

Measurement of humanity among interns of Internal Medicine Department, Damascus University: a cross-sectional study

June 2024

·

10 Reads

International Journal of Surgery Global Health

Tasneem Drie

·

Yara Hodifa

·

Ghina Haidar

·

[...]

·

Maysoun Kudsi

Background Although humanity is important within the medical health field, the authors lack studies that address this topic. Objective The authors aimed to assess humanity among a sample of Syrian internal medicine interns. Methods The authors have used a validated scale based on the Medical Humanity Scale (MHS) categorized into seven human values included in 30 questions (patient-oriented care, respect, empathy, ethics, altruism, and compassion). The scale can test the differentiation between these interns with different levels of medical humanity. A 7-point Likert scale was adopted. Six hundred sixty-five participants from the Internal Medicine Department, Faculty of Medicine, Damascus University entered our study. Results The mean score of the MHS was 147.14 (13.1) Female residents humanity scores (mean 149.14, SD 15.1) was significantly higher than male students’ scores (mean 145.48, SD 13.35; P =.007), KMO=0.843>0.7, which is near 1, and the Bartlett test of sphericity =4187.043 (df=465; P =.01). The Cronbach α was >0.683, was indicating the validity and reliability of the scale. Conclusions The results of this study suggest that the humanity level is accepted by using a scale based on MHS among interns of the Internal Medicine Department, Damascus University.


Laboratory data
A case of multiple myeloma misdiagnosed as seronegative rheumatoid arthritis: a rare case report

April 2024

·

11 Reads

Annals of Medicine and Surgery

Introduction Multiple myeloma (MM) is a malignant plasma cell proliferation producing large numbers of monoclonal immunoglobulins. Typical MM symptoms include anemia, bone pain, hypercalcemia, and renal failure. Atypical presentations like joint involvement were rarely reported in the literature and may cause significant delays in treatment and adverse outcomes. Case presentation The authors report a case of a 54-year-old female who presented with symmetrical polyarthritis and was misdiagnosed with rheumatoid arthritis. The diagnosis of MM was made after failing many treatments of rheumatoid arthritis and with further laboratory tests and procedures. Conclusion This rare manifestation of MM carries a diagnostic challenge and causes a significant delay in treating such patients. Here, the authors report this unusual initial presentation with a review of several cases in the literature describing similar presentations.


Figure 1. Ulcers on the lower lip.
Figure 2. Pancytopenia.
Pancytopenia as a first presentation of late-onset SLE; a case report

March 2024

·

24 Reads

·

1 Citation

Annals of Medicine and Surgery

Introduction Systemic Lupus Erythematosus is a systemic immune disease that classically occurs in young to middle-aged women and may present with cutaneous, renal, hematologic, neurological, and/or other symptoms at the time of diagnosis. Late-onset Systemic Lupus Erythematosus or Systemic Lupus Erythematosus in the elderly is a subtype that differs from classic Systemic Lupus Erythematosus in terms of age group, clinical symptoms, organ involvement and severity. Case presentation A 63 years old female noted to have pancytopenia. The patient was diagnosed with lupus upon obtaining clinical presentations and serological marker, along with high titers of the antinuclear antibody and/or anti-double-stranded DNA antibody. The patient was managed with glucocorticoids and mycophenolate mofetil therapy, which led to a rapid response. Discussion Late-onset SLE accounts for 2–12% of SLE patients with a minimum age of onset of 50 years and older, leading to significant delays in diagnosis. Late-onset SLE differs from early-onset SLE in terms of gender and ethnicity prevalence, clinical symptoms and signs, development of organ damage, disease activity and severity, and prognosis .Some studies have also shown that late-stage SLE patients have higher rates of RF and anti-Ro/anti-La antibody positivity, lower complement titer, and higher incidence of elevated creatinine and decreased creatinine clearance .First-line treatment of pancytopenia is glucocorticoid. In refractory cases, rituximab and immunosuppressants can be used. Conclusion It is important to assess any unusual presentation of Systemic Lupus Erythematosus when clinical suspicion remains high and conducting further laboratory and imaging investigation.


Leukopenia that successfully treated by Ustekinumab in patient with psoriatic arthritis

February 2024

·

25 Reads

International Journal Of Medical Science And Clinical Invention

Introduction:Psoriatic Arthritis (PsA) is an immune-mediated disease. The effectiveness of biologics has changed therapeutic strategies for psoriasis. We report a case of leukopenia in a patient with psoriatic arthritis (PsA) who was treated with Ustekinumab. Case presentation: A 36- year- old Syrian female presented for a follow up concerning treatment of psoriatic arthritis. She was diagnosed with psoriatic arthritis according to the CASPAR criteria. She was treated with Methotrexate, then Sulfasalazine. On presentation, the physical examination revealed tender in metacarpals, proximal interphalengal joints and distal interphalengal joints of both hands. Laboratory analysis showed: white blood cells (WBC) :3500 /mm3, (Neut:23% n = 40-65%, Lymp:65% n= 25-40%), erythrocyte sedimentation rate (ESR): 40 mm/h1, and C-reactive protein (CRP): 9.3 mg/L . Given the patient’s ongoing disease activity, and the presence of leukopenia, we started with Ustekinumab 45 mg subcutaneous. After the third dose of Ustekinumab, evaluation showed improvement in her peripheral arthritis and normal laboratory findings. Discussion: Patients with psoriasis had higher total white blood cell and neutrophil. Ustekinumab has good efficacy against disease activity as well as a favourable safety profile. In literature, we found a case of myelodysplastic syndrome associated with inflammatory bowel disease treated with Ustekinumab. Another case of constitutional neutropenia and psoriasis vulgaris treated with Ustekinumab. Conclusion: This is the first case of leukopenia associated with PsA successfully treated with Ustekinumab. UST treatment might be recommended for leukopenia associated with PsA, but further researches are recommended.


Figure 1. Shows bilateral effusion.
Figure 2. Shows a result of renal biopsy.
Figure 3. Show the child.
Successful pregnancy after cyclophosphamide therapy for systemic lupus erythematosus: A case report

January 2024

·

33 Reads

·

2 Citations

Annals of Medicine and Surgery

Introduction and Importance The use of cyclophosphamide in women of childbearing age with severe systemic lupus erythematosus is normally indicated. However, cyclophosphamide is generally avoided during pregnancy due to the risk of teratogenicity, especially since its effect on fetal survival is poorly understood. This is a case report of a lupus patient exposed to cyclophosphamide during pregnancy. Case Presentation A 35-year-old woman with a history of lupus presented to our outpatient clinic in the 12th week of pregnancy for her 6 th routine cyclophosphamide bolus. The fetal echocardiogram result with gynecology consultation was normal with the recommendation for a medical termination of pregnancy, which has been refused by the patient. Shared decision-making with the patient included a discussion of maternal risks of continuation of pregnancy in the setting of worsening systemic function and the fetal risks of definitive treatment with cyclophosphamide for a lupus flare and the patient decided to proceed with the pregnancy. Treatment with immunosuppressants, including azathioprine was initiated replacing cyclophosphamide with close monitoring of her and the fetus every month. Clinical Discussion The first trimester of pregnancy seems to be particularly susceptible to fetal malformations, although CPA effects on fetuses in later stages of pregnancy are also reported occasionally. Nonetheless, its repercussions on fetal survival remain poorly comprehended. Conclusion In conclusion, exposing pregnancy to cyclophosphamide could end with pregnancy loss. Based on our experience, the survival of the fetus is strongly in doubt when cyclophosphamide is required to treat lupus in the mother. However, in rare cases, it could be without complications.


Rhupus syndrome. a case report of a rare combination

November 2023

·

32 Reads

Annals of Medicine and Surgery

Introduction and importance Rhupus syndrome is a very rare combination of systemic lupus erythematosus and rheumatoid arthritis. It is characterized by the presence of erosive arthritis with symptoms and signs of systemic lupus erythematosus. Rheumatoid nodules and neurological and renal involvement are further complications of Rhupus syndrome, leading to a worse prognosis. Case presentation We presented a young female patient diagnosed with lupus erythematosus, who laterally, developed clinical signs and biomarkers that led to the diagnosis of Rhupus syndrome. This is believed to be of relevance to the knowledge of the medical community. Conclusion Despite being a rare entity, it is important to know its early diagnosis, and treatment to reduce the complications


The mean platelet volume (MPV) in patients with Systemic lupus erythematosus (SLE), and its correlation with disease activity: A cross-sectional/case-control study

October 2023

·

71 Reads

Annals of Medicine and Surgery

Introduction Systemic lupus erythematosus (SLE) is a systemic disease, with unknown etiology. We aimed in our study to determine the connection between Mean Platelet Volume and disease activity of Systemic lupus erythematosus (SLE). Although it has been studied in other rheumatological conditions like rheumatoid Arthritis, its role in adult patients with Systemic lupus erythematosus needs to be defined, especially in Syria. Material and Methods We have included in a cross-sectional study, 80 patients with Systemic lupus erythematosus and 80 controls. The SLE group was divided into two groups based on their disease activity index: the active disease group, and the non-active disease group. In all groups, Mean Platelet Volume, and erythrocyte sedimentation rate (ESR) were analyzed. Clinical findings and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) were evaluated in all patients. Results Mean platelet volume (MPV) was significantly lower in SLE patients compared to the control group (8.49±1.2 fl, and 10.0±0.5fl, respectively) ( P =0.001). A decrease in mean platelet volume (MPV) below the cut-off value (7.2 fl) increased the risk of active disease by an odds ratio of 9.79 (95% CI: 3.4–27.9) ( P <0.001) Conclusion Nean platelet volume may be a disease activity indicator in patients with SLE. MPV is reduced in patients with active SLE and presents an inverse correlation with Systemic Lupus Erythematosus Disease Activity Index(SLEDAI).


A case report of sarcoidosis overlapped with Sjogren’s syndrome

September 2023

·

94 Reads

·

2 Citations

Annals of Medicine and Surgery

Introduction and importance The diagnosis of sarcoidosis and Sjögren’s syndrome (SS) in the same patient is a challenge since sarcoidosis is considered an exclusion criterion for SS. Case presentation The authors described a 62-year-old woman, who had SS for 8 years and presented with dry mouth, dry eyes, dyspnoea, and erythema nodosum. High resolution computed tomography of the chest showed symmetrical pulmonary micronodules, interstitial changes, and enlarged mediastinal lymph nodes. Anti-nuclear antibodies and anti-SSA antibodies were positive. Schermer’s test was also positive. A biopsy of lung nodules revealed non-caseous granuloma. Salivary gland biopsy showed focal lymphocyte infiltration. Diagnosis of sarcoidosis and SS were done according to the classification criteria in this patient. Clinical discussion Although the diagnosis of Sjogren requires the exclusion of conditions that cause dry eyes and mouth, such as sarcoidosis, Few studies have reported the coexistence of sarcoidosis and SS such as this case report. Conclusion This case extends our understanding of overlapped SS with sarcoidosis and provides a referential value for clinical diagnosis.



Citations (4)


... However, some studies suggest using a higher age cutoff of 65 years and older to define l-SLE patients [5]. Since SLE is typically considered a disease affecting young or adult patients, the delay in diagnosing l-SLE is significant and has been reported to be up to 60 months [7]. Lateonset SLE differs from early-onset SLE (e-SLE) in several aspects, including gender and ethnicity prevalence, clinical manifestations, laboratory outcomes, progression of organ damage, disease activity and severity, prognosis, and mortality [5,[7][8][9]. ...

Reference:

CLINICAL FEATURES OF LATE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS
Pancytopenia as a first presentation of late-onset SLE; a case report

Annals of Medicine and Surgery

... Well-known side toxic effects of conventional doses of cyclophosphamide are nausea, alopecia, infertility, pulmonary fibrosis, bladder injury, etc [9,10]. Furthermore, CP has carcinogenic and teratogenic potential [4,11]. ...

Successful pregnancy after cyclophosphamide therapy for systemic lupus erythematosus: A case report

Annals of Medicine and Surgery

... Frequent symptoms include fever, joint pain, weight loss, and fatigue. In addition, other systemic organs symptoms may find at the disease onset or develop as the disease progresses [2] . Late-onset SLE was found to occur in patients over 50-60 years of age [1] . ...

Genital Ulcers Associated with Systemic Lupus Erythematosus - What are the Possible Causes? A Case Report

European Journal of Case Reports in Internal Medicine

... It frequently occurs in the fifth decade of life, with a female predominance and increased risk of developing life-threatening complications, such as lymphoma [4,5] . It is HIGHLIGHTS • Sjögren's syndrome (SS) is a systemic auto-immune syndrome, manifested by dry eyes and mouth. ...

Neurological injury in primary Sjogren's syndrome

Annals of Medicine and Surgery